All articles tagged with #icotyde
A 47-year-old woman with plaque psoriasis endures years of failed treatments and emotional distress until she joins a clinical trial for ICOTYDE, the first oral therapy approved for the condition. Her symptoms dramatically clear, transforming both her skin and self-confidence, and she urges others not to let disease define them.
A 47-year-old woman, Amber Dean, suffered years of physical and emotional torment from plaque psoriasis, enduring misdiagnoses and failed treatments until she joined a clinical trial for ICOTYDE, the first oral medication for the condition. She now reports full skin clearance and a renewed sense of self, calling the decision one of her best health choices and urging others not to be defined by the disease.
Johnson & Johnson won U.S. approval for Icotyde, a daily oral medication for moderate-to-severe plaque psoriasis in patients 12 and older, designed to mimic the effects of top-selling injectables like Skyrizi and Tremfya without injections. The pill could expand the patient market and is projected to reach more than $5 billion in peak annual sales, potentially reshaping competition in a multibillion-dollar field.
The FDA approved ICOTYDE (icotrokinra), the first oral peptide that selectively blocks the IL-23 receptor, for adults and adolescents 12+ weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In Phase 3 ICONIC trials, about 70% achieved IGA 0/1 and 55% reached PASI-90 by Week 16, with adverse events similar to placebo through Week 16 and no new safety signals through Week 52, suggesting a convenient once-daily option that could shift systemic treatment patterns. Johnson & Johnson notes patient support via ICOTYDE withMe and collaboration with Protagonist Therapeutics.